ReviewReviews in endocrine & metabolic disorders2024
Hypoprolactinemia. Does it matter? Redefining the hypopituitarism and return from a mumpsimus : "Absence of proof is not the proof of absence".
Review in Reviews in endocrine & metabolic disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Article
- Association between serum prolactin and anterior pituitary dysfunction in pituitary stalk interruption syndrome: a retrospective study of 155 patients from a large tertiary medical center in China.BMC endocrine disorders · 2026Article
- The impact of hypoprolactinemia on cardiometabolic effects of metformin in young women: a pilot prospective cohort study.Journal of endocrinological investigation · 2025Article
- Diagnosis of hypoprolactinemia.Reviews in endocrine & metabolic disorders · 2024Review
- Could low prolactin levels after radiotherapy predict the onset of hypopituitarism?Reviews in endocrine & metabolic disorders · 2024Review
- What do we know about abnormally low prolactin levels in polycystic ovary syndrome? A narrative review.Reviews in endocrine & metabolic disorders · 2024Review
- Evidence-based definition of hypoprolactinemia in European men aged 40-86 years: the European male ageing study.Reviews in endocrine & metabolic disorders · 2024Review
- Effect of Cabergoline on weight and glucose metabolism in patients with acromegaly.Journal of endocrinological investigation · 2024Article
- An Update on Advances in Hypopituitarism: Etiology, Diagnosis, and Current Management.Journal of clinical medicine · 2024Review
- In Vitro Screening of Trehalose Synbiotics and Their Effects on Early-Lactating Females and Offspring Mice.Antioxidants (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prolactin (PRL) is secreted by the lactotroph cells in the anterior pituitary gland which is under inhibitory control of dopamine. The mature human PRL has more than 300 physiological actions including lactation, reproduction, homeostasis, neuroprotection, behavior, water and electrolyte balance, immunoregulation and embryonic and fetal development. PRL is involved in the growth and development of mammary gland, preparation of the breast for lactation in the postpartum period, synthesis of milk, and maintenance of milk secretion. Abnormalities in the synthesis and secretion of PRL may result in hyperprolactinemia or hypoprolactinemia. Although hyperprolactinemia has been extensively investigated in the literature, because of the subtle or unclearly defined symptoms, hypoprolactinemia is a less-known and neglected disorder. Failure of lactation is a well-known clinical manifestation of hypoprolactinemia. Recent studies reveal that hypoprolactinemia may have some effects beyond lactation such as increased risk for metabolic abnormalities including insulin resistance, abnormal lipid profile, obesity and sexual dysfunction. Very low level of PRL is suggested to be avoided in patients receiving dopamin agonist treatment to prevent unwanted effects of hypoprolactinemia. Another important point is that hypoprolactinemia is not included in the classification of hypopituitarism. Anterior pituitary failure is traditionally classified as isolated, partial and complete (panhypopituitarism) hypopituitarism regardless of prolactin level. Therefore, there are two kinds of panhypopituitarism: panhypopituitarism with normal or high PRL level and panhypopituitarism with low PRL level. In this review, we present two personal cases, discuss the diagnosis of hypoprolactinemia, hypoprolactinemia associated clinical picture and suggest to redefine the classification of hypopituitarism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.